Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Multiple Myeloma 4Neoplasms 2Lymphoma 2Leukemia, Myeloid, Acute 2Leukemia 2Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Lymphoma, Large B-Cell, Diffuse 1Hematologic Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 14fludarabine 10fludarabine phosphate 8Whole-Body Irradiation 7thymoglobulin 5Thiotepa 5Tacrolimus 5Stem Cell Transplantation 5Standard of Care 5Practice Guidelines as Topic 5Nivolumab 5Granulocyte Colony-Stimulating Factor 5Busulfan 5Azacitidine 5venetoclax 4Radiotherapy 4Mycophenolic Acid 4Methotrexate 4Melphalan 4Filgrastim 4Cytarabine 4Antilymphocyte Serum 4Rituximab 3Mesna 3Leucovorin 3Dexamethasone 3Calcium Dobesilate 3Alemtuzumab 3ruxolitinib 2ceritinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Hematologic Neoplasms × isatuximab × Clear all
NCT05284032 2024-07-31

A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001)

University of Virginia

Phase EARLY_PHASE1 Terminated
3 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡